Samuel Isaly‘s Orbimed Advisors has disclosed holding a stake in Loxo Oncology Inc (NASDAQ:LOXO). The fund reported buying 275,385 shares in an open-market transaction, at a price of $13 apiece, while another 1.90 million shares have been obtained through the conversion of Series A convertible preferred stock. In this way, Orbimed currently holds around 2.18 million shares of Loxo Oncology Inc (NASDAQ:LOXO), the activist stake amassing 13.65% of the company’s common stock.
Orbimed Advisors also was one of the investors of the company before it went public, being mentioned among the principal stockholders, in Loxo Oncology’s S-1 filing with the SEC. Loxo Oncology Inc (NASDAQ:LOXO) is a small cap healthcare company, engaged in the development of small molecule therapeutics for targeted treatment of cancer. The company went public at the beginning of the month. James Flynn‘s Deerfield Management has also reported a stake in Loxo Oncology Inc (NASDAQ:LOXO), disclosing ownership of 1.59 million shares, its passive stake being equal to almost 10% of the company’s outstanding stock.